Cancer Letters
Volume 220, Issue 1 , Pages 49-55 , 18 March 2005

The combination of Jun N-terminal kinase inhibitor and TNP-470 blocks carcinosarcoma-induced endothelial cell tube formation in a synergistic manner

  • Shin-ichiro Miura

      Affiliations

    • Department of Cardiology, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-92-801-1011; fax: +81-91-865-2692.
    • ,
  • Makoto Emoto

      Affiliations

    • Department of Obstetrics and Gynecology, Fukuoka University School of Medicine, Fukuoka, Japan
    • ,
  • Yoshino Matsuo

      Affiliations

    • Department of Cardiology, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan
    • ,
  • Tatsuhiko Kawarabayashi

      Affiliations

    • Department of Obstetrics and Gynecology, Fukuoka University School of Medicine, Fukuoka, Japan
    • ,
  • Keijiro Saku

      Affiliations

    • Department of Cardiology, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan

Received 13 February 2004 ,Revised 21 June 2004 ,Accepted 25 June 2004.

References 

  1. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994;76:1025–1037
  2. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 1995;270:16483–16486
  3. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl Acad. Sci. USA. 2001;98:13681–13686
  4. Shin M, Yan C, Boyd D. An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim. Biophys. Acta. 2002;1589:311–316
  5. Dong C, Yang DD, Wysk M, Whitmarsh AJ, Davis RJ, Flavell RA. Defective T cell differentiation in the absence of Jnk1. Science. 1998;282:2092–2095
  6. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 2000;288:870–874
  7. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J. Clin. Invest. 1999;103:1231–1236
  8. Griffith EC, Su Z, Niwayama S, Ramsay CA, Chang YH, Liu JO. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc. Natl Acad. Sci. USA. 1998;95:15183–15188
  9. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 1990;348:555–557
  10. Kusaka M, Sudo K. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem. Biophys. Res. Commun. 1991;174:1070–1076
  11. Miura S, Emoto M, Matsuo Y, Kawarabayashi T, Saku K. Carcinosarcoma-induced endothelial cells tube formation through KDR/Flk-1 is blocked by TNP-470. Cancer Lett. 2004;203:45–50
  12. Emoto M, Iwasaki H, Kikuchi M, Ishiguro M, Kubota T, Izumi H, et al. Two cell lines established from mixed mullerian tumors of the uterus. Morphologic, immunocytochemical, and cytogenetic analyses. Cancer. 1992;69:1759–1768
  13. Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br. J. Cancer. 1994;69:212–216
  14. Emoto M, Iwasaki H, Oshima K, Kikuchi M, Kaneko Y, Kawarabayashi T. Characteristics of rhabdomyosarcoma cell lines derived from uterine carcinosarcomas. Virchows Arch. 1997;431:249–256
  15. Miura S, Matsuo Y, Saku K. Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension. 2003;41:1118–1123
  16. Miura S, Fujino M, Matsuo Y, Kawamura A, Tanigawa H, Nishikawa H, et al. High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2003;23:802–808
  17. Vilcek J, Lee TH. Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J. Biol. Chem. 1991;266:7313–7316
  18. Rutault K, Hazzalin CA, Mahadevan LC. Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-alpha) mRNA induction. Evidence for selective destabilization of TNF-alpha transcripts. J. Biol. Chem. 2001;276:6666–6674
  19. Tournier C, Hess P, Yang DD. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 2000;288:870–874
  20. Maki Y, Bos TJ, Davis C, Starbuck M, Vogt PK. Avian sarcoma virus 17 carries the jun oncogene. Proc. Natl Acad. Sci. USA. 1987;84:2848–2852
  21. Soprano KJ, Cosenza SC, Yumet G, Soprano DR. Use of antisense oligomers to study the role of c-jun in G1 progression. Ann. N Y Acad. Sci. 1992;660:231–239
  22. Bost F, McKay R, Bost M, Potapova O, Dean NM, Mercola D. The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol. Cell Biol. 1999;19:1938–1949
  23. Desai SB, Libutti SK. Tumor angiogenesis and endothelial cell modulatory factors. J. Immunother. 1999;22:186–211
  24. Norris HJ, Taylor HB. A clinical and pathologic study of 31 carcinosarcomas. Cancer. 1966;19:1459–1465
  25. Östör AG, Rollason TP. Mixed tumours of the uterus. In:  Fox H,  Wells M editor. fourth ed.. Haines and Taylor. Obstetrical and Gynaecological Pathology. vol. 1:New York, NY: Churchill Livingstone; 1995;p. 606–610
  26. Emoto M, Iwasaki H, Ishiguro M, Ishiguro M, Kikuchi M, Horiuchi S, et al. Angiogenesis in carcinosarcomas of the uterus: differences in the microvessel density and expression of vascular endothelial growth factor between the epithelial and mesenchymal elements. Hum. Pathol. 1999;30:1232–1241
  27. Emoto M, Udo T, Kubota M, Kawarabayashi T, Ishiguro M, Iwasaki H, et al. Neovascularization of uterine carcinosarcoma: a report of two cases analyzed by color doppler ultrasound and microvessel density. J. Ultrasound Med. 1999;18:315–319
  28. Fisher C, Gilbertson-Beadling S, Powers EA, Petzold G, Poorman R, Mitchell MA. Interstitial collagenase is required for angiogenesis in vitro. Dev. Biol. 1994;162:499–510
  29. Samantaray S, Sharma R, Chattopadhyaya TK, Gupta SD, Ralhan R. Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2004;130:37–44
  30. Sheu BC, Lien HC, Ho HN, Lin HH, Chow SN, Huang SC, et al. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res. 2003;63:6537–6542
  31. Kraling BM, Wiederschain DG, Boehm T, Rehn M, Mulliken JB, Moses MA. The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro. J. Cell Sci. 1999;112:1599–1609
  32. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 1998;93:411–422
  33. Woo JH, Lim JH, Kim YH, Suh SI, Min DS, Chang JS, et al. Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene. 2003;1–9
  34. Wang BW, Chang H, Lin S, Kuan P, Shyu KG. Induction of matrix metalloproteinases-14 and -2 by cyclical mechanical stretch is mediated by tumor necrosis factor-alpha in cultured human umbilical vein endothelial cells. Cardiovasc. Res. 2003;59:460–469

PII: S0304-3835(04)00509-9

doi: 10.1016/j.canlet.2004.06.048

Cancer Letters
Volume 220, Issue 1 , Pages 49-55 , 18 March 2005

Article Tools

* Image Usage & Resolution